HU9203162D0 - Method for diastereoselective reductive pinacolic binding of homoquiralic alpha-amino-aldehydes - Google Patents
Method for diastereoselective reductive pinacolic binding of homoquiralic alpha-amino-aldehydesInfo
- Publication number
- HU9203162D0 HU9203162D0 HU9203162A HU9203162A HU9203162D0 HU 9203162 D0 HU9203162 D0 HU 9203162D0 HU 9203162 A HU9203162 A HU 9203162A HU 9203162 A HU9203162 A HU 9203162A HU 9203162 D0 HU9203162 D0 HU 9203162D0
- Authority
- HU
- Hungary
- Prior art keywords
- homoquiralic
- pinacolic
- aldehydes
- alpha
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL99759A IL99759A (en) | 1991-10-16 | 1991-10-16 | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
Publications (3)
Publication Number | Publication Date |
---|---|
HU9203162D0 true HU9203162D0 (en) | 1992-12-28 |
HUT67218A HUT67218A (en) | 1995-03-28 |
HU217589B HU217589B (hu) | 2000-02-28 |
Family
ID=11062970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9203162A HU217589B (hu) | 1991-10-16 | 1992-10-06 | N-propargil-1-amino-indán monofluorszármazékai és ezeket tartalmazó gyógyászati készítmények, valamint eljárás a vegyületek és a gyógyászati készítmények előállítására |
Country Status (16)
Country | Link |
---|---|
US (1) | US5486541A (hu) |
EP (1) | EP0538134B1 (hu) |
JP (1) | JP3247165B2 (hu) |
CN (1) | CN1038928C (hu) |
AT (1) | ATE149999T1 (hu) |
AU (1) | AU649565B2 (hu) |
CA (1) | CA2079968C (hu) |
DE (1) | DE69218101T2 (hu) |
DK (1) | DK0538134T3 (hu) |
ES (1) | ES2101063T3 (hu) |
FI (1) | FI113262B (hu) |
GR (1) | GR3023556T3 (hu) |
HU (1) | HU217589B (hu) |
IL (2) | IL112819A (hu) |
NZ (1) | NZ244616A (hu) |
ZA (1) | ZA927570B (hu) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
US5708018A (en) * | 1993-08-06 | 1998-01-13 | Pharmacia & Upjohn Company | 2-aminoindans as selective dopamine D3 ligands |
IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
AU1867095A (en) * | 1994-01-10 | 1995-08-01 | Technion Research & Development Foundation Ltd. | 1-aminoindan derivatives and compositions thereof |
US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
US6211235B1 (en) | 1996-11-22 | 2001-04-03 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting β-amyloid peptide release and/or its synthesis |
US6191166B1 (en) * | 1997-11-21 | 2001-02-20 | Elan Pharmaceuticals, Inc. | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis |
DK0966435T3 (da) | 1996-12-18 | 2005-08-15 | Teva Pharma | Aminoindanderivater |
US6683075B1 (en) | 1996-12-23 | 2004-01-27 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use |
US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
GB9715082D0 (en) * | 1997-07-17 | 1997-09-24 | Scherer Ltd R P | Treatment of attention deficit hyperactivity disorder and narcolepsy |
US6528505B1 (en) | 1998-06-22 | 2003-03-04 | Elan Pharmaceuticals, Inc. | Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6552013B1 (en) | 1998-06-22 | 2003-04-22 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6569851B1 (en) * | 1998-06-22 | 2003-05-27 | Elan Pharmaceutials, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6774125B2 (en) * | 1998-06-22 | 2004-08-10 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
AU775885B2 (en) | 1999-10-27 | 2004-08-19 | Teva Pharmaceutical Industries Ltd. | Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder |
AU2001255646A1 (en) * | 2000-05-04 | 2001-11-12 | Warner Lambert Company | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives |
TWI290549B (en) * | 2000-06-02 | 2007-12-01 | Astrazeneca Ab | Process for the preparation of cyclopropyl carboxylic acid ester and derivatives |
US20020151526A1 (en) * | 2000-10-06 | 2002-10-17 | Gallop Mark A. | Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism |
US6956129B2 (en) | 2001-02-16 | 2005-10-18 | Bayer Aktiengesellschaft | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives |
US20040010038A1 (en) * | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
US7396860B2 (en) * | 2002-11-15 | 2008-07-08 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
US20050192265A1 (en) * | 2003-03-20 | 2005-09-01 | Thompson Richard C. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
EP1686973A4 (en) * | 2003-11-25 | 2009-03-25 | Technion Res & Dev Foundation | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISEASES |
US20080090915A1 (en) * | 2003-11-25 | 2008-04-17 | Technion Research And Development Foundation Ltd. | Method for preventing or attenuating anthracycline-induced cardiotoxicity |
US8097608B2 (en) | 2003-11-25 | 2012-01-17 | Technion Research And Development Foundation Ltd. | Methods for treatment of cardiovascular disorders and diseases |
JP2008507586A (ja) * | 2004-07-26 | 2008-03-13 | テバ ファーマシューティカル インダストリーズ リミティド | ラサグリンを含む、医薬投与剤 |
US20060025446A1 (en) * | 2004-07-27 | 2006-02-02 | Jeffrey Sterling | Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders |
PL1848415T3 (pl) * | 2005-02-17 | 2013-10-31 | Teva Pharma | Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego |
US20100167983A1 (en) * | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
NZ560660A (en) | 2005-02-23 | 2010-11-26 | Teva Pharma | Rasagiline ( R(+)-N-propargyl-1-aminodan ) formulations of improved content uniformity |
WO2006130707A2 (en) * | 2005-06-02 | 2006-12-07 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
US8263655B2 (en) * | 2005-10-06 | 2012-09-11 | Technion Research And Development Foundation Ltd | Methods for treatment of renal failure |
CA2630037C (en) | 2005-11-17 | 2015-03-31 | Teva Pharmaceutical Industries Ltd. | Methods for isolating propargylated aminoindans |
US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
ES2632638T3 (es) | 2005-12-09 | 2017-09-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Ladostigilo de baja dosis para el tratamiento de la deficiencia cognitiva |
US8809310B2 (en) | 2006-02-21 | 2014-08-19 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
TW200744576A (en) | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
WO2007117431A2 (en) * | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
JP5356248B2 (ja) * | 2006-12-14 | 2013-12-04 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンのタンニン酸塩 |
ES2375761T3 (es) * | 2006-12-14 | 2012-03-06 | Teva Pharmaceutical Industries Ltd. | Base de rasagilina cristalina sólida. |
EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
US20090062400A1 (en) * | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
EP2053033A1 (en) | 2007-10-26 | 2009-04-29 | Bayer Schering Pharma AG | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors |
EP2234478A4 (en) * | 2008-01-11 | 2013-01-23 | Teva Pharma | RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE |
US20100008983A1 (en) * | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
BRPI0909894A2 (pt) * | 2008-06-13 | 2015-07-28 | Teva Pharma | "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica. |
JP2011524907A (ja) * | 2008-06-19 | 2011-09-08 | テバ ファーマシューティカル インダストリーズ リミティド | 固体ラサギリン塩基を調製および乾燥する方法 |
AU2009260733B2 (en) * | 2008-06-19 | 2015-01-29 | Teva Pharmaceutical Industries, Ltd. | Process for purifying rasagiline base |
CN102264689B (zh) * | 2008-12-22 | 2014-12-31 | 新梅斯托克尔卡公司 | 制备伊伐布雷定的方法 |
US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
RS53504B1 (en) | 2009-07-09 | 2015-02-27 | Ratiopharm Gmbh | RAZAGILIN SALTS AND THEIR PHARMACEUTICAL PREPARATIONS |
WO2011087791A1 (en) * | 2009-12-22 | 2011-07-21 | Teva Pharmaceutical Industries Ltd. | 3-keto-n-propargyl-1-aminoindan |
BR112012019374B1 (pt) | 2010-02-03 | 2022-01-11 | Pharma Two B Ltd | Composição farmacêutica oral e uso de um agente ativo para a preparação de uma composição farmacêutica oral para o tratamento de doenças neurodegenerativas |
US8691872B2 (en) | 2010-07-27 | 2014-04-08 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
JP2013533287A (ja) | 2010-07-27 | 2013-08-22 | テバ ファーマシューティカル インダストリーズ リミティド | 嗅覚機能不全の処置のためのラサギリンの使用 |
EA201490761A1 (ru) | 2011-10-10 | 2014-11-28 | Тева Фармасьютикал Индастриз Лтд. | R(+)-n-формилпропаргиламиноиндан |
EP2766004A4 (en) | 2011-10-10 | 2015-04-22 | Teva Pharma | R (+) - N-methyl-propargyl-aminoindan |
EP2884972A4 (en) | 2012-08-17 | 2016-05-11 | Teva Pharma | PARENTERAL FORMULATION OF RASAGILINE |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3201470A (en) * | 1965-08-17 | Chsx c cech | ||
US3253037A (en) * | 1962-06-19 | 1966-05-24 | Ciba Geigy Corp | N-2-alkynyl-amino-benzocylo-alkanes |
GB1187017A (en) * | 1966-07-16 | 1970-04-08 | Aspro Nicholas Ltd | Substituted 1-Amino Indanes and Tetrahydronaphthalens |
GB1033686A (en) * | 1965-05-10 | 1966-06-22 | Maximilian Heller | Improvements in convertible double bed settees |
HU207282B (en) * | 1984-05-31 | 1993-03-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them |
HU208484B (en) * | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
-
1991
- 1991-10-16 IL IL11281991A patent/IL112819A/en not_active IP Right Cessation
- 1991-10-16 IL IL99759A patent/IL99759A/xx not_active IP Right Cessation
-
1992
- 1992-09-30 AU AU26063/92A patent/AU649565B2/en not_active Ceased
- 1992-10-01 ZA ZA927570A patent/ZA927570B/xx unknown
- 1992-10-02 FI FI924458A patent/FI113262B/fi active
- 1992-10-05 NZ NZ244616A patent/NZ244616A/en not_active IP Right Cessation
- 1992-10-06 CA CA002079968A patent/CA2079968C/en not_active Expired - Fee Related
- 1992-10-06 HU HU9203162A patent/HU217589B/hu not_active IP Right Cessation
- 1992-10-14 CN CN92113070A patent/CN1038928C/zh not_active Expired - Fee Related
- 1992-10-15 DK DK92402821.0T patent/DK0538134T3/da active
- 1992-10-15 AT AT92402821T patent/ATE149999T1/de not_active IP Right Cessation
- 1992-10-15 EP EP92402821A patent/EP0538134B1/en not_active Expired - Lifetime
- 1992-10-15 DE DE69218101T patent/DE69218101T2/de not_active Expired - Fee Related
- 1992-10-15 JP JP27731492A patent/JP3247165B2/ja not_active Expired - Fee Related
- 1992-10-15 ES ES92402821T patent/ES2101063T3/es not_active Expired - Lifetime
-
1994
- 1994-09-22 US US08/310,480 patent/US5486541A/en not_active Expired - Lifetime
-
1997
- 1997-05-26 GR GR970401207T patent/GR3023556T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2079968C (en) | 2004-12-21 |
ATE149999T1 (de) | 1997-03-15 |
IL99759A0 (en) | 1992-08-18 |
JPH05262701A (ja) | 1993-10-12 |
ZA927570B (en) | 1993-04-14 |
AU2606392A (en) | 1993-04-22 |
IL112819A (en) | 2001-11-25 |
FI924458A (fi) | 1993-04-17 |
CA2079968A1 (en) | 1993-04-17 |
ES2101063T3 (es) | 1997-07-01 |
FI113262B (fi) | 2004-03-31 |
EP0538134B1 (en) | 1997-03-12 |
HU217589B (hu) | 2000-02-28 |
CN1038928C (zh) | 1998-07-01 |
DE69218101T2 (de) | 1997-09-25 |
FI924458A0 (fi) | 1992-10-02 |
IL99759A (en) | 1997-06-10 |
GR3023556T3 (en) | 1997-08-29 |
DK0538134T3 (da) | 1997-04-01 |
EP0538134A2 (en) | 1993-04-21 |
NZ244616A (en) | 1995-04-27 |
CN1073427A (zh) | 1993-06-23 |
US5486541A (en) | 1996-01-23 |
EP0538134A3 (en) | 1993-06-16 |
DE69218101D1 (de) | 1997-04-17 |
AU649565B2 (en) | 1994-05-26 |
HUT67218A (en) | 1995-03-28 |
JP3247165B2 (ja) | 2002-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU9203162D0 (en) | Method for diastereoselective reductive pinacolic binding of homoquiralic alpha-amino-aldehydes | |
IL130260A0 (en) | 3-thiocarbamoylpyrazole derivatives as pesticides | |
EE200000318A (et) | Uudsed ühendid | |
GB9822473D0 (en) | Chemical compounds | |
SE9901875D0 (sv) | Novel compounds | |
ZA977240B (en) | Novel benzamidines | |
BG103310A (en) | Benzonaphthyridins as bronchial therapeutical means | |
GR3036305T3 (en) | Chiral methyl phenyl oxazolidinones | |
IL116584A0 (en) | Novel flavin adenine dinucleotide analogue inhibitors of monoamine oxidase | |
ES2185196T3 (es) | Un procedimiento para la preparacion de tetraazamacrociclos. | |
MX9700854A (es) | Derivados de azabicicloheptano n-substituidos utiles como neurolepticos. | |
DE69502855D1 (de) | (Pyrrolidinyl)phenylcarbamate und Zwischenverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente | |
IL158356A0 (en) | Benzoheterocycles | |
ATE244706T1 (de) | Enantiomere von mercaptolactonen und verfahren zu ihrer herstellung | |
DE69415264D1 (de) | N-substituierte Aminopyrrolderivate, Verfahren zu ihrer Herstellung und herbizide Zusammensetzungen | |
TR199901092T2 (xx) | Oksazolin türevlerinin hazırlanması için işlem ve ara maddeler. | |
DE69002478D1 (de) | N-substituierte 3-((2,3-dimethylmaleimido)-amino)-benzolsulfonamid-derivate, verfahren zu ihrer herstellung und herbicid wirkende zusammensetzungen. | |
ZA919079B (en) | A process for the preparation of a 3-alkylated indole | |
DE60030428D1 (de) | 4-cyano-3-hydroxy-butanoyl hydrazine, derivate und verfahren zu ihrer herstellung | |
ZA983523B (en) | New benzyl amine derivatives and phenyl ethyl amine derivatives process for preparing them and their use as medicaments | |
ATE34386T1 (de) | 1,2,3,4-tetrahydro-1-aminomethyl-4-phenylisochinoline und verfahren zu ihrer herstellung. | |
MXPA02003516A (es) | Clorihidrato de n-[3-[[2-(3,4-dimetoxifenil)etil]amino[propil]-4-nitrobenzamida polimorfico. | |
MY103392A (en) | Stabilisation of cholorofluoroalkanes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FH91 | Appointment of a representative |
Free format text: FORMER REPRESENTATIVE(S): DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU Representative=s name: PARRAGH GABORNE DR., S.B.G. & K. SZABADALMI UE, HU |
|
FH92 | Termination of representative |
Representative=s name: DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU |
|
MM4A | Lapse of definitive patent protection due to non-payment of fees |